Enhanced vertical alveolar bone augmentation by recombinant human bone morphogenetic protein-2 with a carrier in rats.
Identifieur interne : 002038 ( PubMed/Checkpoint ); précédent : 002037; suivant : 002039Enhanced vertical alveolar bone augmentation by recombinant human bone morphogenetic protein-2 with a carrier in rats.
Auteurs : C. Shimazu [Japon] ; T. Hara ; Y. Kinuta ; K. Moriya ; Y. Maruo ; S. Hanada ; S. MinagiSource :
- Journal of oral rehabilitation [ 0305-182X ] ; 2006.
Descripteurs français
- KwdFr :
- Acide lactique, Acide polyglycolique, Animaux, Facteur de croissance transformant bêta (usage thérapeutique), Matériaux biocompatibles, Microscopie électronique, Mâchoire édentée (anatomopathologie), Mâchoire édentée (physiopathologie), Mâle, Ostéoblastes (anatomopathologie), Polymères, Processus alvéolaire (anatomopathologie), Processus alvéolaire (physiopathologie), Protéine morphogénétique osseuse de type 2, Protéines morphogénétiques osseuses (usage thérapeutique), Protéines recombinantes (usage thérapeutique), Rat Wistar, Rats, Reconstruction de crête alvéolaire (), Régénération osseuse (), Substituts osseux (usage thérapeutique), Éponge de gélatine résorbable.
- MESH :
- anatomopathologie : Mâchoire édentée, Ostéoblastes, Processus alvéolaire.
- physiopathologie : Mâchoire édentée, Processus alvéolaire.
- usage thérapeutique : Facteur de croissance transformant bêta, Protéines morphogénétiques osseuses, Protéines recombinantes, Substituts osseux.
- Acide lactique, Acide polyglycolique, Animaux, Matériaux biocompatibles, Microscopie électronique, Mâle, Polymères, Protéine morphogénétique osseuse de type 2, Rat Wistar, Rats, Reconstruction de crête alvéolaire, Régénération osseuse, Éponge de gélatine résorbable.
English descriptors
- KwdEn :
- Alveolar Process (pathology), Alveolar Process (physiopathology), Alveolar Ridge Augmentation (methods), Animals, Biocompatible Materials, Bone Morphogenetic Protein 2, Bone Morphogenetic Proteins (therapeutic use), Bone Regeneration (drug effects), Bone Substitutes (therapeutic use), Gelatin Sponge, Absorbable, Jaw, Edentulous (pathology), Jaw, Edentulous (physiopathology), Lactic Acid, Male, Microscopy, Electron, Osteoblasts (pathology), Polyglycolic Acid, Polymers, Rats, Rats, Wistar, Recombinant Proteins (therapeutic use), Transforming Growth Factor beta (therapeutic use).
- MESH :
- chemical , therapeutic use : Bone Morphogenetic Proteins, Bone Substitutes, Recombinant Proteins, Transforming Growth Factor beta.
- chemical : Biocompatible Materials, Bone Morphogenetic Protein 2, Lactic Acid, Polyglycolic Acid, Polymers.
- drug effects : Bone Regeneration.
- methods : Alveolar Ridge Augmentation.
- pathology : Alveolar Process, Jaw, Edentulous, Osteoblasts.
- physiopathology : Alveolar Process, Jaw, Edentulous.
- Animals, Gelatin Sponge, Absorbable, Male, Microscopy, Electron, Rats, Rats, Wistar.
Abstract
This study aimed to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on vertical bone regeneration of edentulous ridge. Bilateral upper first and second molars of 8-week-old Wistar rats were extracted and the ridges were allowed to heal for 3 weeks. Compressed poly(lactic-co-glycolic acid) copolymer/gelatin sponge (PGS) was used as a carrier of rhBMP-2. PGS alone (control group) or PGS with 5 mug rhBMP-2 (test group) was implanted at the top part of alveolar ridge. The sham group received no implantation. The rats were killed at 1, 2, 4, 8 and 12 weeks after implantation and examined histologically and histomorphometrically. In the test group, significant bone augmentation was evident on the alveolar ridge throughout the experimental period. Histomorphometric analysis revealed greater tissue volume and height of alveolar bone in the test group compared with the control and sham groups (P < 0.05) from 4 weeks onward and the augmented tissues (5 mm3 in tissue volume and 1.5 mm in bone height) were maintained until 12 weeks. Osteoblast surface increased at 2 and 4 weeks and osteoid thickness reached a peak (25 microm) at 2 weeks. Dynamic variables, which represented calcification, were higher in the test group than the control and sham groups at 4 and 8 weeks (P < 0.05). These results suggest that use of rhBMP-2/PGS may achieve vertical bone augmentation, and stabilizes denture prosthesis or makes up for inadequate bone mass for implant prosthesis.
DOI: 10.1111/j.1365-2842.2005.01593.x
PubMed: 16856959
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16856959Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Enhanced vertical alveolar bone augmentation by recombinant human bone morphogenetic protein-2 with a carrier in rats.</title>
<author><name sortKey="Shimazu, C" sort="Shimazu, C" uniqKey="Shimazu C" first="C" last="Shimazu">C. Shimazu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Occlusal and Oral Functional Rehabilitation, Okayama University Graduate School of Medicine and Dentistry, Okayama City, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Occlusal and Oral Functional Rehabilitation, Okayama University Graduate School of Medicine and Dentistry, Okayama City</wicri:regionArea>
<wicri:noRegion>Okayama City</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hara, T" sort="Hara, T" uniqKey="Hara T" first="T" last="Hara">T. Hara</name>
</author>
<author><name sortKey="Kinuta, Y" sort="Kinuta, Y" uniqKey="Kinuta Y" first="Y" last="Kinuta">Y. Kinuta</name>
</author>
<author><name sortKey="Moriya, K" sort="Moriya, K" uniqKey="Moriya K" first="K" last="Moriya">K. Moriya</name>
</author>
<author><name sortKey="Maruo, Y" sort="Maruo, Y" uniqKey="Maruo Y" first="Y" last="Maruo">Y. Maruo</name>
</author>
<author><name sortKey="Hanada, S" sort="Hanada, S" uniqKey="Hanada S" first="S" last="Hanada">S. Hanada</name>
</author>
<author><name sortKey="Minagi, S" sort="Minagi, S" uniqKey="Minagi S" first="S" last="Minagi">S. Minagi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16856959</idno>
<idno type="pmid">16856959</idno>
<idno type="doi">10.1111/j.1365-2842.2005.01593.x</idno>
<idno type="wicri:Area/PubMed/Corpus">002692</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002692</idno>
<idno type="wicri:Area/PubMed/Curation">002692</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002692</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002692</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002692</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Enhanced vertical alveolar bone augmentation by recombinant human bone morphogenetic protein-2 with a carrier in rats.</title>
<author><name sortKey="Shimazu, C" sort="Shimazu, C" uniqKey="Shimazu C" first="C" last="Shimazu">C. Shimazu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Occlusal and Oral Functional Rehabilitation, Okayama University Graduate School of Medicine and Dentistry, Okayama City, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Occlusal and Oral Functional Rehabilitation, Okayama University Graduate School of Medicine and Dentistry, Okayama City</wicri:regionArea>
<wicri:noRegion>Okayama City</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hara, T" sort="Hara, T" uniqKey="Hara T" first="T" last="Hara">T. Hara</name>
</author>
<author><name sortKey="Kinuta, Y" sort="Kinuta, Y" uniqKey="Kinuta Y" first="Y" last="Kinuta">Y. Kinuta</name>
</author>
<author><name sortKey="Moriya, K" sort="Moriya, K" uniqKey="Moriya K" first="K" last="Moriya">K. Moriya</name>
</author>
<author><name sortKey="Maruo, Y" sort="Maruo, Y" uniqKey="Maruo Y" first="Y" last="Maruo">Y. Maruo</name>
</author>
<author><name sortKey="Hanada, S" sort="Hanada, S" uniqKey="Hanada S" first="S" last="Hanada">S. Hanada</name>
</author>
<author><name sortKey="Minagi, S" sort="Minagi, S" uniqKey="Minagi S" first="S" last="Minagi">S. Minagi</name>
</author>
</analytic>
<series><title level="j">Journal of oral rehabilitation</title>
<idno type="ISSN">0305-182X</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alveolar Process (pathology)</term>
<term>Alveolar Process (physiopathology)</term>
<term>Alveolar Ridge Augmentation (methods)</term>
<term>Animals</term>
<term>Biocompatible Materials</term>
<term>Bone Morphogenetic Protein 2</term>
<term>Bone Morphogenetic Proteins (therapeutic use)</term>
<term>Bone Regeneration (drug effects)</term>
<term>Bone Substitutes (therapeutic use)</term>
<term>Gelatin Sponge, Absorbable</term>
<term>Jaw, Edentulous (pathology)</term>
<term>Jaw, Edentulous (physiopathology)</term>
<term>Lactic Acid</term>
<term>Male</term>
<term>Microscopy, Electron</term>
<term>Osteoblasts (pathology)</term>
<term>Polyglycolic Acid</term>
<term>Polymers</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>Transforming Growth Factor beta (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide lactique</term>
<term>Acide polyglycolique</term>
<term>Animaux</term>
<term>Facteur de croissance transformant bêta (usage thérapeutique)</term>
<term>Matériaux biocompatibles</term>
<term>Microscopie électronique</term>
<term>Mâchoire édentée (anatomopathologie)</term>
<term>Mâchoire édentée (physiopathologie)</term>
<term>Mâle</term>
<term>Ostéoblastes (anatomopathologie)</term>
<term>Polymères</term>
<term>Processus alvéolaire (anatomopathologie)</term>
<term>Processus alvéolaire (physiopathologie)</term>
<term>Protéine morphogénétique osseuse de type 2</term>
<term>Protéines morphogénétiques osseuses (usage thérapeutique)</term>
<term>Protéines recombinantes (usage thérapeutique)</term>
<term>Rat Wistar</term>
<term>Rats</term>
<term>Reconstruction de crête alvéolaire ()</term>
<term>Régénération osseuse ()</term>
<term>Substituts osseux (usage thérapeutique)</term>
<term>Éponge de gélatine résorbable</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Morphogenetic Proteins</term>
<term>Bone Substitutes</term>
<term>Recombinant Proteins</term>
<term>Transforming Growth Factor beta</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biocompatible Materials</term>
<term>Bone Morphogenetic Protein 2</term>
<term>Lactic Acid</term>
<term>Polyglycolic Acid</term>
<term>Polymers</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mâchoire édentée</term>
<term>Ostéoblastes</term>
<term>Processus alvéolaire</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Regeneration</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Alveolar Ridge Augmentation</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Alveolar Process</term>
<term>Jaw, Edentulous</term>
<term>Osteoblasts</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Mâchoire édentée</term>
<term>Processus alvéolaire</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Alveolar Process</term>
<term>Jaw, Edentulous</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Facteur de croissance transformant bêta</term>
<term>Protéines morphogénétiques osseuses</term>
<term>Protéines recombinantes</term>
<term>Substituts osseux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Gelatin Sponge, Absorbable</term>
<term>Male</term>
<term>Microscopy, Electron</term>
<term>Rats</term>
<term>Rats, Wistar</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Acide lactique</term>
<term>Acide polyglycolique</term>
<term>Animaux</term>
<term>Matériaux biocompatibles</term>
<term>Microscopie électronique</term>
<term>Mâle</term>
<term>Polymères</term>
<term>Protéine morphogénétique osseuse de type 2</term>
<term>Rat Wistar</term>
<term>Rats</term>
<term>Reconstruction de crête alvéolaire</term>
<term>Régénération osseuse</term>
<term>Éponge de gélatine résorbable</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This study aimed to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on vertical bone regeneration of edentulous ridge. Bilateral upper first and second molars of 8-week-old Wistar rats were extracted and the ridges were allowed to heal for 3 weeks. Compressed poly(lactic-co-glycolic acid) copolymer/gelatin sponge (PGS) was used as a carrier of rhBMP-2. PGS alone (control group) or PGS with 5 mug rhBMP-2 (test group) was implanted at the top part of alveolar ridge. The sham group received no implantation. The rats were killed at 1, 2, 4, 8 and 12 weeks after implantation and examined histologically and histomorphometrically. In the test group, significant bone augmentation was evident on the alveolar ridge throughout the experimental period. Histomorphometric analysis revealed greater tissue volume and height of alveolar bone in the test group compared with the control and sham groups (P < 0.05) from 4 weeks onward and the augmented tissues (5 mm3 in tissue volume and 1.5 mm in bone height) were maintained until 12 weeks. Osteoblast surface increased at 2 and 4 weeks and osteoid thickness reached a peak (25 microm) at 2 weeks. Dynamic variables, which represented calcification, were higher in the test group than the control and sham groups at 4 and 8 weeks (P < 0.05). These results suggest that use of rhBMP-2/PGS may achieve vertical bone augmentation, and stabilizes denture prosthesis or makes up for inadequate bone mass for implant prosthesis.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16856959</PMID>
<DateCompleted><Year>2007</Year>
<Month>03</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0305-182X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>33</Volume>
<Issue>8</Issue>
<PubDate><Year>2006</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of oral rehabilitation</Title>
<ISOAbbreviation>J Oral Rehabil</ISOAbbreviation>
</Journal>
<ArticleTitle>Enhanced vertical alveolar bone augmentation by recombinant human bone morphogenetic protein-2 with a carrier in rats.</ArticleTitle>
<Pagination><MedlinePgn>609-18</MedlinePgn>
</Pagination>
<Abstract><AbstractText>This study aimed to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on vertical bone regeneration of edentulous ridge. Bilateral upper first and second molars of 8-week-old Wistar rats were extracted and the ridges were allowed to heal for 3 weeks. Compressed poly(lactic-co-glycolic acid) copolymer/gelatin sponge (PGS) was used as a carrier of rhBMP-2. PGS alone (control group) or PGS with 5 mug rhBMP-2 (test group) was implanted at the top part of alveolar ridge. The sham group received no implantation. The rats were killed at 1, 2, 4, 8 and 12 weeks after implantation and examined histologically and histomorphometrically. In the test group, significant bone augmentation was evident on the alveolar ridge throughout the experimental period. Histomorphometric analysis revealed greater tissue volume and height of alveolar bone in the test group compared with the control and sham groups (P < 0.05) from 4 weeks onward and the augmented tissues (5 mm3 in tissue volume and 1.5 mm in bone height) were maintained until 12 weeks. Osteoblast surface increased at 2 and 4 weeks and osteoid thickness reached a peak (25 microm) at 2 weeks. Dynamic variables, which represented calcification, were higher in the test group than the control and sham groups at 4 and 8 weeks (P < 0.05). These results suggest that use of rhBMP-2/PGS may achieve vertical bone augmentation, and stabilizes denture prosthesis or makes up for inadequate bone mass for implant prosthesis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shimazu</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Occlusal and Oral Functional Rehabilitation, Okayama University Graduate School of Medicine and Dentistry, Okayama City, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hara</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kinuta</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moriya</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Maruo</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hanada</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Minagi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D023362">Evaluation Studies</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Oral Rehabil</MedlineTA>
<NlmUniqueID>0433604</NlmUniqueID>
<ISSNLinking>0305-182X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055396">Bone Morphogenetic Protein 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019485">Bone Morphogenetic Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018786">Bone Substitutes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C043435">polylactic acid-polyglycolic acid copolymer</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C499469">recombinant human bone morphogenetic protein-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>26009-03-0</RegistryNumber>
<NameOfSubstance UI="D011100">Polyglycolic Acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>D</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000539" MajorTopicYN="N">Alveolar Process</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000540" MajorTopicYN="N">Alveolar Ridge Augmentation</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055396" MajorTopicYN="N">Bone Morphogenetic Protein 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019485" MajorTopicYN="N">Bone Morphogenetic Proteins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001861" MajorTopicYN="N">Bone Regeneration</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018786" MajorTopicYN="N">Bone Substitutes</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005781" MajorTopicYN="N">Gelatin Sponge, Absorbable</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007575" MajorTopicYN="N">Jaw, Edentulous</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010006" MajorTopicYN="N">Osteoblasts</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011100" MajorTopicYN="N">Polyglycolic Acid</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>3</Month>
<Day>16</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16856959</ArticleId>
<ArticleId IdType="pii">JOR1593</ArticleId>
<ArticleId IdType="doi">10.1111/j.1365-2842.2005.01593.x</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><noCountry><name sortKey="Hanada, S" sort="Hanada, S" uniqKey="Hanada S" first="S" last="Hanada">S. Hanada</name>
<name sortKey="Hara, T" sort="Hara, T" uniqKey="Hara T" first="T" last="Hara">T. Hara</name>
<name sortKey="Kinuta, Y" sort="Kinuta, Y" uniqKey="Kinuta Y" first="Y" last="Kinuta">Y. Kinuta</name>
<name sortKey="Maruo, Y" sort="Maruo, Y" uniqKey="Maruo Y" first="Y" last="Maruo">Y. Maruo</name>
<name sortKey="Minagi, S" sort="Minagi, S" uniqKey="Minagi S" first="S" last="Minagi">S. Minagi</name>
<name sortKey="Moriya, K" sort="Moriya, K" uniqKey="Moriya K" first="K" last="Moriya">K. Moriya</name>
</noCountry>
<country name="Japon"><noRegion><name sortKey="Shimazu, C" sort="Shimazu, C" uniqKey="Shimazu C" first="C" last="Shimazu">C. Shimazu</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002038 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002038 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= EdenteV2 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:16856959 |texte= Enhanced vertical alveolar bone augmentation by recombinant human bone morphogenetic protein-2 with a carrier in rats. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16856959" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a EdenteV2
![]() | This area was generated with Dilib version V0.6.32. | ![]() |